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PREFACE 
Fish culture, a growing industry, has increased the 
demand for therapeutic agents. Due to the lack of pharmaco-
kinetic studies in fish, the use of effective antibacterial 
agents are either based on studies in other animals or 
prohibited by FDA. This study was undertaken to gain an 
understanding of the pharmacokinetics of the antimicrobial 
agent, sulfachlorpyridazine (SCP) in fish. Comparison of 
the pharmacokinetics of this drug with other well studied 
groups of animal were expected to provide evidence for or 
against the potential usefulness of SCP as a therapeutic 
agent for catfish. 
This study was supported by professional developmental 
money from the College of Veterinary Medicine to Dr. Lester 
Rolf. Without his generous help and advice, this study would 
have never materialized. Thanks are extended to Dr. G. 
Burrows and Dr. s. Sangiah for their informative support 
and advice. The auther deeply appreciates the kind assis-
tance of Drs. G. Gebhart and C. Kleinholz of the Oklahoma 
Cooperative Fish and Wild Life Research Unit in obtaining 
the catfish for this study. Many thanks to Dr. B. Lessley 
for his helpfull instruction in using the word processor. 
Graditude for kind moral support of dear friends Hamid Amou-
zadeh, Mary Bober and Michael Smith is expressed. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Antibacterials in Teleosts 
Fish health is affected by a number of pathogenic 
microorganisms. Some of the most debilitating of these 
microorganisms are gram negative bacteria of the genera 
Aerornonas, Vibrio, Pseudomonas, Myxobacteria (Kingsford, 
1975; Conroy, 1963; Van Duijan, 1973; Herman, 1970), 
Hemophilus and Edwardsiella (Aoki and Kitao, 1981). 1These 
i 
bacteria are responsible for the common fish disease~, 
furunculosis, ulcer, cotton wool and tail or fin rot 
(Snieszko, et al., 1974; Van Duijan, 1973). Treatmen~ of 
non-food fish for the above diseases with sulfonamid~s, 
tetracyclines, aminoglycosides and chloramphenicol hks 
proved to be effective and is recommended accordingly 
(Kingsford, 1975; Herman, 1970). 
Growing public concern about the possible unknown 
effects of drugs in fish intended for human consumption, 
has limited the use of various antibacterial agents. As 
more research and evaluation of antibiotics are carried 
out, an increasing number of these therapeutic agents may 
be approved by the United States Food and Drug Adminis-
1 
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tration (FDA) for use in aquaculture. At present, the FDA 
permits the use of salt, acetic acid, formalin, sulfa-
merazine and tetracycline in certain diseases of trout, 
salmon and catfish (Siderman, 1970: Snieszko, et al., 1974). 
The most efficient and practical method of treatment 
of a large number of fish in aquaculture is by water 
treatment or medicated feed (Herman, 1970: Conroy, 1963: 
Herwing, 1979). This technique requires good water 
solubility, thermal stability and oral bioavailability of 
the theraputic agent. Water treatment tends to have a 
prophylactic effect on healthy fish, as well as the 
prevention of further progress of the disease in the 
unhealthy fish, allowing time for immunological defense 
mechanism activation. A theraputic agent, that meets at 
least some of these criteria, is sulfachlorpyridazine (SCP) 
In addition, very desirable pharmacokinetic parameters have 
been demonstrated in various animal species (Romvary and 
Horvay, 1976a, 1976b: Friis, et al., 1980). Sulfachlor-
pyridazine is one of the most effective sulfonamides for 
use in gram negative bacterial disease conditions (Neipp 
and Mayer, 1957; Domagk, 1957: Archibald, and McKay, 1964). 
It is highly water soluble and possesses a high therapeutic 
index. These characteristics rank SCP among the better 
antibacterial agents for treatment of gram negative 
bacterial disease in aquatic and non-aquatic animals. 
Rational treatment requires an appropriate pharmacokinetic 
study of that drug in that particular animal. Inter and 
intraphylatic differences make it not only unreasonable 
but potentially dangerous to extrapolate pharmacokinetic 
parameters of an individual drug or class of agents~ The 
objectives of this research were desiged to evaluate the 
following: (a) Bioavailability of orally administered SCP, 
(b) Variables of tissue and plasma disposition kinetics, 
(c) Protein and tissue binding of SCP and (d) Advantages 
of availability of kinetic parameters for application of 
SCP as a possible therapeutic agent in the treatment of 
channel catfish. 
In 1932, the therapeutic value of prontosil, an azo 
dye was discoverd by German scientists (Struller, 1968). 
Subsequent research at the Pasture Institute showed :that 
an in vivo metabolite of prontosil, para-aminobenzene-
sulfonamide (Hawking, et al., 1950; Haviga, et al., 1946) 
was the molecule responsible for therapeutic efficacy. 
Shortly thereafter, recognition of the therapeutic value 
3 
of sulfonamides was responsible for the initiation of 
research efforts that lead to the development of more active 
sulfonamides. The objectives of such research were 
development of an ideal sulfonamide, one that possesses: 
high efficacy, near complete oral bioavailability, high 
water solubility at neutral pH and low toxicity. These 
efforts lead to the synthesis of over 8000 derivitives of 
sulfanilamide (Northy, 1948; Archibald and McKay, 1964). 
At present, only eight or nine are marketed for huma.n and 
veterinary use. The demonstration of a synergistic action 
4 
of sulfonamides with trimethoprim has brought about a 
resurgence in world wide use of sulfonamides during the 
last 15 years (Rosselet, et al., 1981; Miller and Greenbalt, 
1979). Some of the sulfonamides used to effectively treat 
cotton wool disease, red mouth disease and ulcer diseases 
in fish are sulfamethzine, sulfisoxazole and sulfamerazine 
(Van Duijan, 1973; Snieszko, et al., 1974). 
The variable pKa's of sulfonamides play an important 
role in their rates of elimination and nephrotoxicity 
(Notari, 1980). Sulfonamides, being weak acids, ionize in 
basic solutions. Ionization can decrease their reabsorption 
by the tubules in the kidney, which will increase the 
elimination rate and reduce the nephrotoxicity potential 
of the drug. Crystaluria, one of the primary potential 
problems associated with sulfonamide usage, occurs due to 
reduced solubility of the parent compound and it's N-4 
acetylated (see figure 1) metabolite. To reduce precipi-
tation, alkalinization of urine and intake of large 
quantities of water have been recommended (Goodman, et al., 
1980; Gottschalk, et al., 1960). 
Pharmacology of Sulfachlorpyridazine 
Sulfachlorpyridazine, N(6-chloro-3-pyridazinyl)benzen-
sulfanilamide, a drivitive of sulfanilamide, has a pKa of 
5.9 (Wiseman, 1965; Struller, 1968; Nielsen and Rasmussen, 
1977). The elimination half life of SCP varies from species 
to species. The reported half life in cattle, geese, 
piglets and humans is 1.16, 1.89, 3.01 and 8 hours respec-
tively (Nielsen and Rasmussen, 1977; Romvary and Horvay, 
1976a, 197Gb; Friis, et al., 1980). In one study a half 
life of 11.5 hours for normal adult men is indicated, (Jones 
I 
and Finland, 1975). Sulfachlorpyridazine is considered to 
be a short acting sulfonamide because of rapid renall 
5 
clearance due to tubular secretion and glomerular filtration 
(Siderman, 1970; Friis, et al., 1980). Clearance of unbound 
drug by tubular secretion is noted to be six times faster 
than the clearance by way of glomerular filtration (~delbeck 
Fredeuksen and Rasmussen, 1964). 
0 0 
NH2 so4 NH 
N--N 
Figure 1. Chemical Structure of Sulfa-
chlorpyridazine. 
Cl 
The antibacterial activity of SCP and other sulfona-
mides, resides in the sulfanilamide portion which resembles 
p-aminobenzoic acid (Figure 1). The 6-chloro-3-pyriazinyl 
side group of SCP determines the specific solubility, pKa 
and toxicity of this agent. Low pKa and high water solubil-
ity of SCP appear to decrease it's elimination half life. 
6 
The high water solubility may be partialy responsibl~e for 
the reduced potential of nephrotoxicity when recommended 
doses are administered. The manufacturer's recommend~d 
@ 
intravenous dose of SCP (Vetisulid *) for cattle and swine 
is 65-100 mg/kg and 45-75 mg/kg respectively, for treatment 
of collibacilosis. Variation in the recommended dose are 
based upon the animal species and microorganism 
relationships. 
At present, most of the information on the pharmaco-
kinetic parameters of SCP is derived from studies that have 
been conducted on mammals. Since blood, interstitial fluid 
and urine pH of some fish may be quite different from those 
of mammals, extrapolation from human and other mammals to 
fish is unwise. These differnces as well as differences 
in cardiovascular dynamics, tissue vascularity, metabolism, 
gill elimination, glomerular filtration rates, protein and 
tissue binding may have important effects on the rate of 
elimination, tissue distribution and therefore efficacy 
of sulfachlorpyridazine in fish (Nielsen and Rasmussen, 
1977: Hoar, 1969a). 
Metabolism 
In mammals, sulfonamides undergo variable metabolic 
alteration especially in the liver. The primary metabolites 
(.i) 
*Vetisulid is the tradmark for 
of sulfachlorpyridazine prepared by 
Inc. Princeton, NJ 08540. 
the sodium salt ~olution 
E.R.Squibb & Sons, 
7 
are N-4 acetylated derivitives (see Figure 1), many of which 
are less water soluble than the parent compound and phar-
macologically inert. Acetylation is the result of conjuga-
tion with acetylcoenzyme A under the influence of the proper 
acetyltransferase. From the studies done on the metabolism 
of sulfonamides by rabbit liver, it has been concluded that 
the acetylation reaction takes place in the reticuloendothe-
lial cells rather than the paranchymal cells of the liver 
and other organs (Govier, 1965). The short half life of 
SCP may lower the chance of acetylation. In man, SCP is 
reported to be acetylated to the extent of 20%and exhibits 
a half life of 8 hours, the longest of any species reported 
(Wolf, 1979). Sulfachlorpyridazine is considered to be less 
nephrotoxic than most other sulfonamides as these metab-
olites are very water soluble with little chance of 
-crystaluria (Sieiro and Ameier, 1973). 
A second major metabolite is the N-4 glucuoronide. The 
glucuoronic acid is transferred by glucuronyl transferase 
to the N-4 position of sulfonamides (Figure 1) in the 
liver. The metabolite is excreted into the bile and finally 
into the gastrointestinal tract, where it may be hydrolized 
by gastrointestinal microflora and excreted as such or may 
be reabsorbed (the unionized form) back into the systemic 
circulation as the active drug. The hydroxylation and N-1 
acetylation products are pharmacologically inactive but 
of minor quantitive importance with respect to N-4 acetyla-
tion and glucuronidation. 
Mechanism of Action and 
Bacterial Resistance 
Investigations, as early as the 1940's, postulated 
that many chemotherapeutic agents produce their action 
through effects on essential bacterial metabolites. The 
resemblance between sulfanilamide and para-aminobenzoic 
acid (PABA), led to the theory that the two compounds must 
be competing for a critical enzymatic site and inhibition 
8 
of bacterial growth resulted from reduced enzymatic activity 
(Hawking and Lawrance, 1950; Northy, 1948). This theory 
was strengthened by the discovery of folic acid which 
contains PABA as a portion of it's molecular structure. 
Bacteria synthesize reduced folic acid (tetrahydrofolic 
acid). The process starts by condensation of PABA with 
dihydropteridine and glutamic acid to form dihydrofolic 
acid, which then becomes reduced to tetrahydrofolic acid. 
Sulfonamides present in the environment, can competitively 
inhibit the synthesis of the dihydrofolic acid, therefore 
preventing formation of the coenzyme, tetrahydrofolic acid. 
Inhibition of the coenzyme by sulfonamides can be antag-
onized by minute quantities of PABA: thus inhibition can 
be abolished by as little as lo-4 moles of ?ABA per mole 
of sulfonamide (Struller, 1968). Reduced quantities or a 
complete absence of folic acid prevents one carbon transfer 
and subsequent nucleic acid synthesis by bacteria. This 
inhibitory process leads to a bacteriostatic rather than 
a bacteriocidal action on sensitive organisms. Since host 
9 
tissues acquire preformed folic acid from the environment, 
they are not affected by sulfonamides in this respect. With 
the production of refractive isoenzymes or mutations, the 
bacterial cells may acquire the capability of by-passing 
this "blockade" and developing partial or complete 
resistance. 
Physiochemical Properties of 
Sulfachlorpyridazine 
Passage of SCP and other chemicals across membranes, 
a lipid bilayer, is dependent on the lipid solubility and 
availability of a nonionized form of the chemical. The 
concentration of the nonionized portion depends on the pH 
of the environment and the pKa of the specific sulfonamide 
(Schanker, et al., 1957). Sulfachlorpyridazine as the sodium 
salt, is soluble to the extend of 20 % in water at a pH 
of 7.9. In a bufferd medium with a pH range of 6.5 to 7.0 
0 
and temperature of 37 C sulfachlorpyridazine is 25 times 
more soluble than sulfadiazine (Neip and Mayer, 1957) Lipid 
solubility can be measured by the partitioning of a chemical 
between an aqueous. and oil phase. Frequently, 1-butanol 
is used as a representative of the microbial membran~ 
bilayer. The nonionized portion of the drug will enter the 
oil phase. The relationship between the lipid solubility 
and the half life of several sulfonamides has been studied 
(Rieder, 1963; Schanker, et al., 1957). It is evident that 
long acting sulfonamides are in general more lipid soluable 
10 
than short acting sulfonamides (Struller, 1968). This 
relationship is also affected by protein binding and the 
ambient pH. Protein binding of sulfonamides has always been 
considered very critical in the evaluation of their anti-
bacterial action, since only the unbound sulfonamide finds 
it's way out of the blood vessels into the interstitial 
fluid. Bound sulfonamide is unable to exert it's antibacte-
rial action. Available studies show that protein binding 
of sulfonamides becomes critical when binding is in the 
80 % range (Nielson and Rasmussen, 1977; Anton, 1959). 
Sulfachlorpyridazine binding to plasma proteins of different 
species is enormously variable. In vitro studies have dem-
onstrated plasma protein binding in the range of 54 to 59 
% in pigs (Friis, et al., 1980) and a 80 to 85 %range in 
cows (Nielsen and Rasmussen, 1977). Binding of SCP to human 
plasma protein has been investigated by numerous researchers 
and the reported values show a range of 80 to 98 % (Marino, 
et al., 1979). The enhaced protein binding may advantage 
certain sulfonamides in their antibacterial activity. This 
suggestion is supported by a number of clinical studies 
which indicate that sulfonamides with a high degree of 
protein binding tend to be more rather than less effective 
antimicrobial agents (Witzgall, 1963)· The logic resides 
in the binding of sulfonamides to bacterial protein but 
findings on the affinity of sulfonamides to binding sites 
in bacteria may be relatively specific for certain 
compounds~ and independent of their plasma protein binding 
(Rieder and Bohni, 1963: Anton, 1960). 
Renal and General Systemic Circulation 
in Channel Catfish 
11 
Channel catfish kidneys are divided into cranial (an 
endocrine organ) and caudal portions (excretory organ) and 
refered to as the head and trunk kidney respectively. The 
trunk kidney of catfish, in common with freshwater teleosts, 
are hyperosmotic regulators. The main function of these 
organs is the conservation of filtered electrolytes, 
filteration of waste in the blood and regulation of plasma 
pH to a small degree. In the catfish, renal ion regulating 
activity produces an alkaline urine with a pH of nea~ 7.4 
(Cameron, 1980; Hoar, 1969a). 
The fish circulatory system is significantly different 
from that of mammals in several respects. First, there is 
only a two chamber heart. Secondly, the gill capillaries 
(see Figure 2) are in series with the rest of the systemic 
capilaries in contrast to the pulmonary and systemic 
circulatory capillaries in mammals which are parallel to 
one another. Pulse pressure in the dorsl aorta is usually 
less than 50 % of that in the ventral aorta. The capillary 
bed in the gills represents a considerable portion of the 
total vascular resistance. The blood volume of both marine 
and fresh water teleosts is about 3 % of the body weight 
with pH ranging from 7.5 to 7.9 (Hoar, 1969b). It has been 
shown that at 26°C the pH of the channel catfish's blood 
Source: 
CAUDAL A. __.., 
CAUDAL V. 
-
VRIN8 
Grizzle, J. M. and Rogers, W. A.: Anatomy and Histology of the Channel Catfish. 
Department of Fisheries and Allied Aquaculture, Auburn University Agricultural 
Experiment Station. Auburn, Alabama: Auburn Printrng, Inc., 1976. 
Figure 2. A Diagram of Blood Flow in Major Arteries and Veins to the Vital Organs 
of Channel Catfish. 
1-' 
!\) 
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and intracellular spaces is 7.75 and 7.35 respectively. The 
alkalinity of these fluids will decrease at a rate of 0.018 
pH units per ~ C of rise in the surrounding temperature 
(Cameron, 1980; Reeves, 1977). 
CHAPTER II 
MATERIALS AND METHODS 
General Information 
An injectable sodium salt preparation (VetisulidUU) 
of sulfachlorpyridazine, was obtained from the teaching 
hospital at the Veterinary School of Oklahoma State 
00 
University. Each milliliter of Vetisulid contained 215 mg/ml 
of sodium sulfachlorpyridazine equivalent to 200 mg/ml of 
SCP acid. Benzyl alcohol and sodium hydroxide are used as 
preservative and to adjust the pH of the solution to 9.10 
respectively. 
Channel catfish, Ictalurus punctatus, ranging in 
weight from 120-945 grams were obtained from Oklahoma State 
University Fisheries and Wildlife Unit and private aquacul-
turists in Oklahoma. The catfish were transported in a 10 
gallon plastic can which was oxygenated via a small hose 
from a full oxygen cylinder. In the lab fish were gradually 
introduced into a 75 gallon tank to prevent sudden tern-
perature shock. The water in the holding tank in the lab 
was continously filtered through a submerged charcoal and 
gravel cartridge filter. The chlorine level was minimized 
14 
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by adding about 28 ml of 1 % solution of sodium thiosulfate 
and normally aerating the tank for a few days prior to 
introducing fish. Identification of individual fish in the 
tank was done by distinct clippings on the fins and recorded 
next to their weight in the notebook. All the fish were 
acclimated to the tank· in the laboratory for at least 5 
days and fasted a day prior to the experiment. 
Colorimetric Chemical Analysis 
of Sulfachlorpyridazine 
Sulfonamides and sulfachlorpyridazine can be quanti-
tated by the colorimetric method of Bratton and Marshall 
( 1939) • In this method, the 4-amino group (Figure 1 ). of 
the SCP is diazotized with nitrous acid. The excess amount 
of nitrous acid is destroyed with ammonium sulfamate. The 
diazonium intermidiate is coupled with N-(naphtyl)ethylen-
diamine resulting in a pinkish purple color in the test 
tube. The reaction product is then measured spectrophoto-
meterically at 540 nanometers. In these studies a Be,ckman 
: 
DU-8 spectrophotometer was used. A standard curve was 
! 
generated in the usual fashion, over a concentration range 
of 0.2 to 10 pg/ml of.SCP. Exceptional accuracy and i 
linearity of the method was evident at SCP concentra·tions 
to as low as 0.1 pg/ml. The color produced is stable for 
at least 24 hours (Rolf and Hudgins, 1979) but samples were 
usually evaluated spectrophotometrically within 2 hours 
of collection. 
Micronized Analytical Procedure 
for Sulfachlorpyridazine 
16 
The procedure of the Bratton-Marshall method described 
previously was micronized to accomodate the small volumes 
(300 to 500 pl) of blood samples taken from the catfish. The 
blood withdrawn, was transfered to a couple of heparinized 
microhematocrit capillary tubes which were centrifuged to 
separate the plasma from the red cells. One hundred fl of 
plasma with 10 pl of 30 % trichloracetic acid were 
transfered into another capillary tube and centrifuged for 
period of 10 to 15 minutes to precipitate the protein. 
Precipitated protein was separated from the protein free 
extract by fracturing 'the tube and was then transfered into 
a clean watch glass. Ten to 25 fl of the extract, depending 
on the sample time and anticipated SCP concentration, were 
withdrawn by a micropipetter and trasfered into a test tube 
containing 0.5 ml of distilled water. The distilled water 
was used to add volume and to wash off any residue remaining 
in the tip of the micropipetter. Then, 100 fl of the nitrous 
acid were added to the test tube and mixed well so it could 
react with all the SCP present in the solution. After 4 
minutes, 100 fl of the ammonium sulfamate were transfered 
into the test tube and mixed to remove excess nitrous acid. 
After 4 minutes 100 pl of the Bratton-Marshall reagent were 
transfered into the mixture followed by a quick mix for 
color development. The mixture was allowed to stand for 
20 minutes before spectrophotometric measurement of the 
optical density of the solution. Then the standard curve 
was used to determine the concentrations of SCP from the 
optical density of the solutions. 
Fish Plasma Protein Analysis 
by the Hartree r.1ethod 
The concentration of plasma and tissue protein was 
measured by the Hartree method (1972). Protein analysis 
by the Hartree method requires three different reagents 
(solutions A, B and C) which were made prior to the 
analysis: 
Solution (A): 2.0 g of potassium sodium tartrate and 
100.0 g of sodium carbonate dissolved in 500.0 ml. of 1.0 
N sodium hydroxide and dilluted with deionized water to 
1000 ml. 
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Solution (B): 1.0 g of cupric sulfate and 2.0 g of 
potassium sodium tatrate dissolved in 10 ml of 1.0 N sodium 
hydroxide and dilluted with deionized water to 100 ml. 
Solution (C): This solution had to be freshly made 
by mixing 1 part Folin-Ciocalteu reagent to 15 parts 
distilled water. The normality of the solution was kept 
in the 0.15 to 0.18 range with 1.0 N sodium hydroxide. The 
normality of the solution was adjusted with 1.0 N sodium 
hydroxide . 
To determine the protein concentration, 1.0 ml 6f the 
catfish plasma or crude tissue homogenate was dillut~d with 
1.0 ml of deionized water. To this volume 0.9 ml of solution 
(A) was added and incubated in a preheated (50°C) water 
bath for 10 minutes. This sample was cooled at room tem-
perature for 10 more minutes. To the cooled mixture, 0.1 
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ml of solution (B) was added and left at room temperature 
for 10 minutes. Finally, 3.0 ml of the solution (C) were 
transfered into the test tube and placed in the water bath 
for 10 minutes. The samples were cooled at room temperature 
for 30 minutes during which time a light blue color was 
developed. The optical density of the color developed was 
measured at 640 nanometers wavelength by a Beckman DU-8 
spectrophotometer. To evaluate the measured optical density, 
a standard curve was made up from bovine serum albumin 
fraction a, in the concentration range of 1.66 to 8.33 pg 
of albumin per ml of distilled water. 
Sulfachlorpyridazine Intracardiac Administration 
Materials and Methods 
A day prior to an experiment, 1 or 2 fish were marked, 
weighed and fasted. Individuals in these experiments were 
identified as having recieved an intracardiac (Ic) injection 
by including "Ic" after the fish number. The following day, 
a dose of 60 mg/kg of SCP was drawn into a 1.0 ml syringe 
for drug administration. Intracardiac puncture was done 
with a 3/4 inch, 27 gage disposable needle. This needle 
size prevented excessive damage to the heart and minimized 
hemolysis during repeated blood samplings. 
To prevent excessive damage to the epithelial mucoid 
19 
coating which protects the catfish from bacterial infec-
tions, a very smooth cotton cloth was wetted and wrapped 
around the fish before handling. The wet cloth was quite 
effective in immobilization as well as protection. The 
intracardiac puncture was made at a 30 degree angle to the 
ventral surface, under the cleithrum and coracoid bone. To 
insure the placement of the tip of the needle in the heart, 
injection of the drug was preceeded by withdrawal of a small 
amount of blood into the visible part of the needle on the 
syringe. Using the first fish as a trial fish, an appro-
priate sampling schedule was established at 2, 5, 8, 14, 
20, 60, 120, 240, 420, 600, 840, 1200 minutes post injec-
tion. At each time period withdrawn blood was transfered 
into heparinized capillary tubes and centrifuged for 3 to 
5 minutes. After measuring the packed cell volume, plasma 
was transfered into another capillary tube and sealed from 
botb ends. The sealed capillary tube, put into appropriately 
labled test tubes, were stored in a refrigerator till the 
end of the experiment. Concentrations of the SCP in the 
plasma samples were measured as described earlier. The 
intracardiac puncture study was performed on more than 14 
catfish. Unfortunately in some instances the subject died 
in the process of the experiment or it appeared the drug 
may not have been injected into the heart. 
The plasma SCP concentrations {pg/ml) at different 
sampling times of every individual catfish were used to 
generate a time concentration curve on four cycle semi-
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logarithic graph paper. To illustrate the pharmacokinetic 
parameter findings, the time concentration profile for fish 
number 8 (F8Ic) is shown on page 22 (Figure 3). The time-
concentration relationship in a two compartment open kinetic 
model, has two phases with an inflection point between the 
phases. The inflection point was determined by trial and 
error "best fit" of points that appeared to be on either 
side. Phase I represents a complex phase of distribution 
and elimination denoted as a +8. Phase II is considered 
to represent the elimination component of the model, denoted 
as s. The procedure of "feathering" is used to subtract 
the minor elimination component that has occurred during 
distribution of the drug to produce the "pure" distribution 
phase, a (Jones, et al • , 19 7 7) • After feathering, 1 inear 
regression lines were ploted through the plasma values of 
the respective phases. Graphic display of the linear 
regression of the distribution phase was used to find the 
distribution half life, the time frame required for a 
reduction of the plasma concentration by one half, t~ of 
alpha (t~a). From the t~ alpha, alpha, a microconstant 
represnting the rate in reciprocal minutes at which the 
SCP was distributed within the body was calculated by 
Equation (2). Extrapolation of the alpha linear regression 
line back to the Y-intercept yields the theoretical zero 
time concentration, A. 
Phase II, represents the total elimination of the drug 
from the central compartment. The regression of data points 
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in phase II is used to find the elimination half life (t~S) 
which is used to calculate beta, S (beta, a microconstant 
similar to alpha) by Equation (3). The Y-intercept of this 
line is the hypothetical zero time SCP concentration of 
the elimination phase, designated as B. The sum of A and 
B is the total hypothetical concentration of SCP in the 
central compartment (Cp) at time zero. 
Kinetic microconstants of drug movement from the 
central compartment to the tissue (k 12 ) as well as ~he 
reverse (k 21 ) and egress from the central compartment via 
excretion (ke1 ) were calculated using Equations (4), (5) 
and (6) respectively (Appendix C). Area under the curve 
(AUC) for intracardiac administration was calculated 
mathematically by the trapezoid method for comparison with 
the AUC of the oral administration. The volume of distrib-
ution was calculated using the AUC generated by the 
trapezoid method multiplied by beta as in Equation (8), 
in Appendix c. The volume of the central compartment (Vc), 
representing the apparent blood volume in the catfish, was 
determined by the Equation (7). Sulfachlorpyridazine clear-
ance was calculated by Equation (10) using the product of 
AUC·S and by Equation (11) using the product of k 1·Vc. , e 
Theoretical tissue SCP concentrations and fractional 
excretion rates were calculated by the Loo-Riegelman treat-
ment, Equation (13), using the mean plasma SCP concentration 
of all fish given SCP by intracardiac route. 
The mean and standard error (SE) of the raw data and 
derived data were calculated and tabulated with the rest 
of the results in Appendix A and B. 
Sulfachlorpyridazine Oral Administration 
Materials and Methods 
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This experiment was designed to measure the oral bio-
availability of SCP in catfish. To facilitate oral 
administration, a special dosing device was designed to 
deliver a SCP solution in a gelatin capsule. The device 
consisted of a 20 em long outer tube, and a 30 em long inner 
tube used as a plunger for the outer tube. The tip of the 
outer tube was cut at a 45 degree angle at one end to 
reduce resistance at the pharyngeal sphincter and minimize 
trauma. The day prior to experimentation 24 hour fasted 
fish were marked and weighed. Fish identification numbers 
contained (Or) to indicate the route of administration. The 
volume of SCP containing the calculated dose (60 mg/kg) 
was transfered into a gelatin capsule and placed inside 
of the angled end of the outer tube. The catfish was quickly 
restrained and the outer tube was inserted through the 
pharyngeal sphincter. The capsule was propelled from the 
outer tube with the inner plunger. The total time of 
administration was kept within a 2 minute time frame to 
prevent premature dissolution of the gelatin capsule. After 
administration, the fish were released into a small bucket 
with a known volume of water. Analysis of this water in 
the first 5-10 minutes indicated if drug was regurgitated. 
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Using the first fish as a trial fish, the blood sampling 
time after oral administration was scheduled for 30, 60, 
90, 120, 150, 180, 240, 300, 420, 600, 840, 1200 minutes 
post administration. To calculate the individual oral 
bioavailability, every effort was made to repeat the oral 
adminstration experiment on a catfish that had already been 
used for an intracardiac experiment. 
The blood samples were taken and analysed as in the 
intracardiac administration. The plasma concentration of 
the individual catfish were ploted on a 3 cycle semi-log-
arithmic graph paper. A representative plot for F80r is 
given in Figure 4. The log plasma concentration-time curve 
of the oral administration also has two phases, an 
absorption phase and elimination phase. Extrapolation of 
the linear regression line of the elimination phase to the 
Y-axes, was taken as the zero time concentration (B). The 
apparent volume of distribution and clearance were cal-
culated by Equation (8) and (10) using the AUC values and 
the dose or beta. The AUC was calculated by the trapezoid 
method. Bioavailability of SCP in catfish was calculated 
by dividing AUC value of oral administration by the AUC 
value of intracardiac administration of the same fish. Fish 
3, 5 and 7 in the oral studies did not have intracardiac 
injections, therefore the mean AUC value of all the fish 
given SCP by intracardiac injections were used in bioavail-
ability calculations. 
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Lipid Solubility and pH Dependent Partitioning 
of Sulfachlorpyridazine 
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The oil:water partition experiments were designed to 
study the potential effects of the variable pH values of 
catfish body fluids on the ionization state of the SCP in 
relation to it's diffusion kinetics between the gastrointes-
tinal tract, vascular compartment and tissues. The pH of 
separate volumes of monobasic phosphate buffer (0.154 M) 
was adjusted to 6.0, 7.4 and 7.8 by 0.154 M sodium 
hydroxide. Then, 13 small pyrex glass flasks along with 
rubber stoppers, were cleaned and divided into three groups 
of four. A flask filled with 20 ml of distilled water and 
100 pl of SCP (200 mg/ml) were used as a control for the 
amount of SCP delivered by the micropipeter. Ten ml volumes 
of the specified phosphate buffer solution were placed into 
50 ml Erhlenmeyer flask with 10 ml of 1-butanol or dichloro-
ethylene. One hundred pl of SCP stock solution (200 mg/ml) 
were added. After periodic shaking for 5 days at room tem-
perature, aliquots were withdrawn from the flasks. 
Sulfachlorpyridazine concentrations in the aqueous phase 
were determined by the Bratton-Marshall method. The con-
centration of SCP in the phosphate buffer as a percent of 
the amount added was calculated. The partitiion coefficient 
was calculated as the ratio of drug in oil (total drug -
drug in the buffer) to drug in the phosphate buffer. 
Plasma Protein Binding of 
Sulfachlorpyridazine 
The conventional laboratory technique of equilibrium 
dialysis was used to determine the protein binding of SCP. 
This experiment was designed to evaluate the relationship 
between protein binding and varying both ambient pH and 
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drug concentrations. Monobasic potassium phosphate buffers 
(0.154 M) with pH values of 7.8 and 6.0 were prepared. 
Cellophane dialysis tubing was cut into 8 em lengths and 
moistened in distilled water over a period of time. In the 
first phase of the experiment 16 beakers with 10 ml capacity 
were divided into four groups : AI, BI and AII, BII. A and 
B represent the pH of the buffers 7.8 and 6.0 respectively 
and roman numbers indicate the SCP concentration. Into each 
beaker, 9.0 ml of the appropriate buffer were added. The 
dializing tubes were tied at one end to form a bag. Into 
each bag 1.0 ml of pooled catfish plasma along with four 
glass weights were added. The plasma had been previously 
dialysed against the phosphate buffer for 24 hours. The 
open end of the bags were tied up and immersed into the 
buffer containing the specified amount of SCP. Beakers were 
sealed to prevent water evaporation and set aside for two 
days at room temperature with periodic shaking. After 48 
hours the buffer portion was analyzed by the Bratton-
Marshall method. The pooled catfish plasma had a protein 
concentration of 4.8 gm/dl as determined by the Hartree 
method (1972). The concentration of SCP in the buffer 
compartment was multiplied by 9.95 (9 ml buffer + 0.95 ml 
plasma water) to arrive at total unbound SCP. The amount 
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of protein bound SCP was determined by subtracting total 
unbound SCP from total SCP added to the beaker. The percent 
binding was calculated by dividing the protein bound SCP 
by total SCP added to the beaker and multipling by 100. 
Muscle Tissue Binding Of 
Sulfachlorpyridazine 
Muscle tissue constitutes the largest mass of tissue 
in catfish and is the only part commonly consumed by peo-
ple. The interest in this tissue from both a consumption 
and therapeutic point of view makes a binding study impor-
tant. Monobasic potassium phosphate buffer (0.154 M) was 
adjusted to pH 6.0 and 7.8 with 0.154 M sodium hydroxide. 
Beakers with a 30 ml capacity were divided into 2 groups. 
After labeling, 8.0 ml of phosphate buffer were transferred 
into one beaker group with a buffer pH of 6.0 and second 
group with a pH of 7.8. A healthy catfish was killed by 
a blow into the head and about 15 to 20 g· of muscle was 
removed from the sides close to the pelvic fin area. As 
in the plasma binding study, 12 dialysis bags were made 
containig 4 glass weights. After homogenization approximatly 
1.0 g of the homogenate was transferred into each dialysis 
bag and the external surface was washed off with 1.0 ml 
appropriate buffer. The bags were tied up and immersed into 
the buffer. The beakers were sealed with parafilm, with 
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periodic shaking for the next 48 hours. After incubation,the 
buffer SCP concentration was analysed by the Bratton-
Marshall method. 
To calculate tissue water content, a known amount of 
• • 0 
muscle t1ssue was dr1ed at 75 C for 48 hours to a constant 
weight. Percent water was calculated as the wet weight minus 
the dry weight divided by the wet weight and multiplied 
by 100. The percent binding of SCP was determined as in 
the plasma protein binding study. The protein concentration 
of the muscle homogenate was also measured by the Hartree 
method (1972). 
CHAPTER III 
RESULTS 
General Information 
The mean of the determined and calculated values are 
reported throughout this chapter. Sulfachlorpyridazine was 
administered at 60 mg/kg body weight. Using the SCP stock 
solution (200 mg/ml) a standard curve was produced with 
a correlation coefficient of 0.99989 and Y-intercept of 
0.0092. 
The hematocrit was measured for all the blood samples 
taken by intracardiac puncture and an initial mean hemato-
crit of 30 % was noted. In general, the hematocrit dropped 
to 2/3 of the initial volume by the end of the experlment 
after an initial small increase within the first hour. 
The water content of muscle was calculated from the 
difference between the dry and wet weight. On the average, 
water constituted 81 % of the body weight. The protein con-
centration of the fish plasma and muscle as analyzed by 
the Hartree method was 4.8 g/dl and 8.9 g/100 g respec-
tively. 
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Sulfachlorpyridazine Pharmacokinetic Parameters 
After Intracardiac Administration 
The alpha (distribution) half life of SCP was 3.2 min 
with a zero time concentration, A of 2489.6 pg/ml. An alpha 
rate constant (a) of 0.25227 min-1 was calculated. The zero 
time concentration of the elimina~ion phase, B, was 118.5 
pg/ml. A beta half life of 252 min (4.12 hours) and beta 
rate constant {S) of 0.00303 min-1 was calculated. The 
theoretical total SCP concentration in the central compart-
0 
ment, Cp, at zero time was 2608.2 pg/ml. The kinetic 
microconstants k 12 , k21 and ke1 were found to be 0.18344, 
0.01547 and 0.05640 min respectively. The apparent volume 
of distribution, Vd, was 441.8 ml/kg, calculated by dose 
divided by AUC Sand 463.1 ml/kg calculated by ke1 • Vc. The 
apparent volume of the central compartment, calculated from 
the plasma concentration of SCP was 25.7 ml/kg. Correcting 
the plasma value to a whole blood base, the volume of the 
central compartment would be 36.7 ml/kg. The area under the 
curve (AUC) was 514774.6 pg.min/ml. The rate of whole body 
clearance (Cl8 ) of SCP from catfish calculated from Vd(area) 
times S and ke1 times Vc, was 1.21 and 1.27 ml/min/kg 
respectively. The ratio of the two microconstants k 12 over 
k 21 was calculated to be 11.8. The mean plasma and tissue 
SCP concentration along with percent elimination over a 20 
hour period is graphically presented in Figure 5. 
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Sulfachlorpyridazine Pharmacokinetic Parameters 
After Oral Administration 
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The mean beta half life calculated from the slope of 
the beta phase was 265 min with zero time SCP concentration 
(B) of 35.3 pg/ml. The apparent volume of distribution (Vd) 
was 465.3 ml/kg. The whole body clearance, ClB value was 
calculated to be 1.20 ml/min/kg. 
Theoretical tissue concentrations were calculated from 
the average values of required parameters from the oral 
and intracardiac studies. The results indicate that at a 
mean peak plasma concentration of 11.6 pg/ml, the tissue 
SCP concentration (Figure 6) can reach as high as 110 
pg/ml. 
The calculation of bioavailability for the 6 individual 
catfish was possible because the same fish were used for 
both treatments (intracardiac and oral). The mean bioavail-
ability was 13.9 %with a maximum of 31.9 % in fish 9 and 
a minimum of 4.7 % in fish 1. A graphical depiction of mean 
values of SCP in plasma, tissue and a percent excretion 
is shown in Figure 6. 
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Physiochemical Parameters of 
Sulfachlorpyridazine 
35 
Sulfachlorpyridazine equilibrated between phosphate 
buffer at pH 7.8 and 6.0 and 1-butanol, had a partition 
coefficient of 0.21 and 0.16 respectively. The concentration 
of SCP in buffer increased from 87.5 to 91.0 %when the 
pH of the phosphate buffer was reduced from 7.8 to 6.0. The 
partitioning of SCP between phosphate buffer and dichloro-
ethylene had different absolute coefficients but followed 
the pattern established in 1-butanol. At buffer pH values 
of 7.8, 7.4 and 6.0, the partition coefficients were 0.43, 
0.65 and 3.58 respectively. The percentage of SCP in the 
phosphate buffe increased from 21.6 % to 70.3 % as the pH 
was lowered from 7.8 to 6.0. 
Tissue binding of SCP was performed on catfish white 
muscle. Binding studies revealed that at phosphate buffer 
pH of 7.8 and 6.0, the binding was about 19.9 and 22.2 % 
respectively (see Figure 7). Plasma protein binding was 
4 to 5 times lower than tissue binding, at the same SCP 
concentrations. In phosphate buffer of pH 7.8 and 6.0, SCP 
binding to plasma protein was 3.7 and 5.5 % respectively. 
When the same experiment was repeated at lower SCP concen-
trations (about 238 pg) in phosphate buffer pH of 7.8, a 
binding of 1.9 % was observed. In similar experiments with 
208.8 pg of SCP, a binding of 14.2 and 12.1 % was calculated 
at buffer pH values of 7.8 and 6.0. 
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Figure 7. Sulfachlorpyridazine Tissue and Plasma Protein 
Binding 
CHAPTER IV 
DISCUSSION 
Sulfachlorpyridazine concentrations in plasma were 
analyzed with the Bratton-Marshall method and concentrations 
less than 0.2 pg/ml from small volumes of plasma (25 pl) 
were easily and accurately analyzed. Blood samples taken 
within the first 30 minutes after intracardiac injections 
of SCP provided distribution phase kinetics with an average 
half life of 3.2 min. 
The zero time concentration (A) of the alpha (a) phase 
was variable from fish to fish. During injection, patency 
with the cardiac chamber required withdrawing small volumes 
of blood, including the dead space volume, into the needle 
hub which replaced some of the SCP solution. Upon injection 
then the calculated amount of drug, or more, may have been 
injected. 
In most other SCP pharmacokinetic studies (man or 
animals), the kinetics of the distribution phase have not 
been done and/or reported. Kinetics of SCP have been studied 
most frequently on the basis of a one compartment, open 
model. With distinct distribution and elimination phases, 
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SCP in catfish behaves with disposition kinetics best fitted 
to a two compartment open model. The t~S of 4.20 hours after 
intracardiac administration was in close agreement with 
t~S of 4.41 hours after oral administration. The t~S of 
SCP in catfish was as variable within the species as 
reported from different animal species. In this study, a 
range of plasma half life values from 2.1 hours to 6.0 hours 
was observed. The reported t~S of SCP in 2 year old geese 
and piglets is 1.89 and 3.01 hrs respectively (Romvary and 
Horvay, 1976a~ 1976b). It does seem surprising that these 
values are as low as reported. In the case of the piglets, 
the immature renal filteration/secretion capacity and 
probable acidic urine associated with a nursing omnivore 
should have prolonged plasma residence (Friis, et al., 
1980). The alkaline urine of geese and the overall increased 
renal functional capacity in these mature animals is helpful 
in reducing the plasma concentration of SCP very rapidly 
in this species when compared to fish. 
There was less than a 5% difference in the apparent 
volume of distribution for the intracardiac and oral 
administration of SCP. The values reported here are less 
than the intracellular water volumes reported for catfish 
of approximately 600 ml/kg (Cameron, 1980), but does indi-
cate that SCP is present in much of cellular water. Compara-
tively, a value of about half that of catfish, 240 ml/kg 
has been reported in cattle (Nielson and Rasmussen, 1977) 
Clearance of SCP has not been calculated in other 
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studies. Hoar (1969a) reported that the glomerular filtra-
tion rate (GFR) and renal blood flow in fish are approx-
imately 0.13 and 3.1 ml/min/kg respectively. This GFR is 
almost 9 times lower than the Cl of 1.21 ml/min/kg reported B 
for SCP in these fish, indicating a larger percentage of 
elimination by secretion than by filtration. 
Critical to the use of any therapeutic agent is the 
maintenance of the plasma concentrations at levels 
sufficient to keep receptors occupied for a continued 
pharmacological effect. In the case of sulfonamides, the 
minimum inhibitory concentration (MIC) has generally been 
assumed to lie somewhere between 20 fg/ml and 50 fg/ml. The 
rapid elimination of SCP from fish plasma, obviously 
provides large amounts of drug in the urinary system. 
Studies of the theoretical tissue disposition indicate that 
this drug, given by either intracardiac or oral route, can 
exceed tissue levels of 25 pg/ml for 12 hours. Since tissue 
levels have not been correlated to plasma MIC values, it 
is not possible to speculate on the therapeutic relevance 
of these theoretical tissue concentrations. That evaluation 
awaits the actual simultaneous determination of plasma and 
tissue levels. 
Three important factors that may be involved in the 
loculation of SCP in the tissue compartment as seen in these 
studies are ion trapping, tissue binding and lipid 
solubility. Plasma protein binding of SCP has been reported 
to be as high as 98 % in humans (Marino, et, al., 1979), 
40 
85 % in cattle (Nielsen and Rasmussen, 1977) to as low as 
54% in piglets (Friis, et al., 1980). In very sharp 
contrast, the results of this study indicate a very low 
protein binding of SCP to fish plasma protein that is 
relatively pH independent. While this allows a large amount 
of freely diffusible drug for elimination processes, it 
also provides a free moiety for a driving concentration 
gradient into tissue. 
Tissue binding studies suggest that tissue has 4 to 
5 times higher affinity for SCP than plasma proteins. The 
higher affinity of tissue may be regarded as reinforcement 
for SCP use in catfish, since tissue is the environment 
where SCP would be expected to exert it's antibacterial 
activity. A hypothesis supported by experimental findings 
of Witzgall (1963) suggests that the factors responsible 
for high protein binding of sulfonamides may also serve 
to increase their binding to bacterial membrane protein. 
Some of the differences in the affinity of SCP for tissue 
and plasma protein binding can be accounted for by pre-
viously reported selectivity of sulfanomides for different 
proteins (Rieder and Bohni, 1963). 
Ambient pH may alter the ratio of unionized to ionized 
species and interrelate with the lipid solubility in that 
manner. The suggestion from the data is that even the 
ionized form of the SCP molecule, is lipid soluble enough 
to show a greater concentration in the oil phase than could 
be expected based on the pKa and pH. If the latter mechanism 
is operating, then considerably more drug is available for 
membrane penetration and subsequent ion trapping in intra-
cellular spaces. These mechanisms, ion trapping and lipid 
membrane penetration, are obviously important at the oral 
absorptive surface for achivement of bioavailability as 
well as increasing the chance for hepatocyte penetration 
and metabolism, intracellular movement with sequestering 
and reabsorption across renal tubular cells. Barriers such 
as the gastrointestnal mucosa and blood-brain barrier are 
more easily penetrated as lipophilicity of the nonionized 
molecule increases (Shanker, et al., 1957). 
Hematocrit measurement indicated a decline in the 
packed cell volume over the course of blood sampling time. 
Whether the change in the PCV affected the concentrations 
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of SCP in plasma is difficult to document. With an increased 
water content of the blood, the resistance to blood flow 
may have decreased, thus allowing better distribution. The 
volume of blood that was withdrawn at each sampling time 
was minute (about 40 pl) and less than 2 % of the total 
blood volume was removed with each experiment. Stress from 
the repeated blood sampling may have played a greater role 
than actual blood loss in the elimination and other kinetic 
parameters by changing the behavior of the animal. 
CHAPTER V 
CONCLUSION 
This pharmacokinetic study of sulfachlorpyridazine 
(SCP) was oriented toward an understanding of the kinetic 
behavior of this drug in catfish and it's potential as a 
therapeutic agent. With a plasma half life of about 4.2 
hours and an apparent volume of distribution of 450 ml/kg, 
SCP may prove to be a good therapeutic agent for catfish. 
The very favorable tissue:plasma equilibrium provides 
for mean tissue concentrations in excess of 25 fg/ml for 
over 12 hours. It seems likely that some of this favorable 
equilibrium may enhance penetration of SCP into tissue 
compartments, the apparent volume of distribution having 
absolute significance. Tissue binding, though not pH 
depenent, .has significance despite being a small absolute 
amount. The large percentage of the body mass occupied by 
the muscle coupled with ion trapping may explain the 
approximate 10 fold ratio of tissue ingress:egress of SCP. 
Improvement of the 14 % bioavailability of SCP reported 
in these studies makes the therapeutic use of this sulfon-
amide even more appealing. 
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TABLE I 
SULFACHLORPYRIDAZINE STANDARD CURVE 
Sample 
Number 
l 
2 
3 
4 
5 
6 
Slope 
Concentration 
of SCP (J.lg/ml) 
0.2 
1.0 
2.0 
4.0 
6.0 
8.0 
Y-Intercept 
Correlation Coefficient 
Optical Density 
at 540 nm 
0.04440 
0.20786 
0.37420 
0.74906 
1.10890 
1.50700 
0.18566 
0.00916 
0.99989 
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TABLE II 
BOVINE SERUM ALBUMIN STANDARD CURVE 
Sample Bovine Serum Albumin Optical rpensity 
Number Concentration (pg/ml) at 64m nm 
I 
I 
1 1.66 0.01~52 
2 3.33 0.04429 
3 5.55 0.07605 
4 6.66 0.09417 
5 8.33 0.11731 
Slope 0.00245 
Y-Intercept 0.00492 
Correlation Coefficient 0.99985 
Buffer 
pH 
6.0 
6.0 
6.0 
6.0 
Mean 
SE 
7.4 
7.4 
7.4 
7.4 
Mean 
SE 
7.8 
7.8 
7.8 
7.8 
Mean 
SE 
TABLE III 
SULFACHLORPYRIDAZINE PARTITIONING BETWEEN 
POTASSIUM PHOSPHATE BUFFER AND 1-BUTANOL 
SCP Concentration Percent in Partition 
52 
(mg:) 
Buffer 1-Butano1 Buffer Coefficient 
4.51 15.49 22.5 3.44 
4.59 15.41 23.0 3.35 
4.20 15.80 21.0 3.76 
4.18 15.92 20.9 3.78 
----- 21.6 3.58 
----- ±0.5 ± 0.11 
11.75 8.25 58.6 0.70 
12.64 8.36 63.2 0.58 
11.97 8.03 59.9 0.67 
12.05 7.95 60.3 0.66 
----- 60.5 0.65 
----- ±1.0 ± 0 0 03 
14.14 5.85 70.8 0.41 
13.43 6.57 67.2 0.49 
' 
13.76 6.24 68.8 0.45 
14.83 5.17 74.2 0.39 
----- 70.3 0.43 
----- ± 1. 5 ±0.02 
TABLE IV 
SULFACHLORPYRIDAZINE PARTITIONING BETWEEN POTASSIUM 
PHOSPHATE BUFFER AND DICHLOROETHYLENE (DCE~ 
53 
Buffer SCP Concentration (mg) Percent in Partition 
pH Buffer DCE Buffer Coefficient 
7.4 8.37 1.63 88.4 0.19 
7.4 8.19 1.81 86.4 0.22 
7.4 8.18 1.82 86.4 0.22 
7.4 8.43 l. 57 89.0 0.19 
Mean 87.5 0.21 
SE ± 0. 5 ± 0. 01 
7.8 8.81 1.19 93.0 0.14 
7.8 8.45 l. 55 89.0 I o .18 
7.8 8.37 1. 63 88.4 0.20 
7.8 8.94 1.06 94.4 0.12 
Mean 91.3 0.16 
SE ±1.5 ± 0. 02 
~, 
-
TABLE V 
SULFACHLORPYRIDAZINE PLASMA PROTEIN BINDING 
(PART I) 
Buffer Total SCP Total SCP % Protein 
pH Added(pg) Measured(pg) Binding 
7.8 2300.1 2225.8 3.2 
7.8 2300.1 2271.6 1.2 
7.8 2300.1 2189.0 4.8 
7.8 2300.1 2250.7 2.1 
7.8 2300.1 2238.7 2.7 
7.8 2300.1 2189.0 4.8 
7.8 2300.1 2213.9 3.7 
7.8 2106.5 1990.7 5.5 
7.8 2106.5 1975.2 6.2 
7.8 2106.5 1989.8 5.5 
7.8 2106.5 2078.6 1.3 
Mean 
------ ------
3.7 
SE 
------ ------
±o. s 
6.0 2106.5 2053.7 2.5 
6.0 2106.5 1883.5 10.6 
6.0 2106.5 1992.0 5.4 
6.0 2106.5 2031.8 3.5 
, 
Mean 
------ ------
5.5 
SE 
------ ------
±1.8 
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TABLE VI 
SULFACHLORPYRIDAZINE PLASMA PROTEIN BINDING 
(PART II) 
Buffer Total SCP Total SCP % Protein 
pH Added(pg) Measured(pg) Binding 
7.8 238.0 235.4 1.1 
7.8 238.0 234.7 1.4 
7.8 238.0 228.9 3.8 
7.8 238.0 236.1 0.8 
7.8 238.0 233.2 2.0 
7.8 238.0 233.2 2.0 
Mean ----- ----- 1.9 
SE ----- ----- ±0.4 
7.8 208.8 178.3 14.6 
7.8 208.8 178.3 14.6 
7.8 208.8 171.0 13.1 
7.8 208.8 178.5 14.5 
Mean ----- ----- 14.2 
SE ----- ----- ± 0. 4 
6.0 208.8 182.6 12.6 
6.0 208.8 192.4 7.8 
6.0 208.8 187.6 10.2 
6.0 208.8 172.0 17.6 
Mean ----- ----- 12.1 
SE ----- ----- ± 2.1 
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TABLE VII 
SULFACHLORPYRIDAZINE TISSUE BINDING 
Buffer Total SCP Total SCP % Protein 
pH Added(pg) Measured(pg) Binding 
7o8 2230o0 1775o2 22o8 
7o8 2230o0 1911.0 l6o9 
7o8 2299o9 1992o0 l3o4 
7o8 230lo3 1773o3 22o9 
7o8 2299o9 19l6o9 l6o7 
7o8 2299o9 1689o9 26o5 
Mean 2300o2 1843ol l9o9 
SE ±1.6 ±46 0 6 ±2 0 0 
6o0 2300ol 2003o8 l2o8 
6o0 2299o9 1771.1 23o0 
6o0 2300o0 1734o8 24o6 
6o0 2300o0 1817o6 21.0 
6o0 2298o7 1718o0 25o3 
6o0 2300o0 1695o7 26o3 
Mean 2299o8 1790o2 22o2 
SE ±1.4 ±46o 2 ±2 0 0 
Time Post II 
Injection 
(min) 
2 
5 
8 
14 
20 
60 
120 
180 
240 
360 
420 
600 
840 
1200 
TABLE VIII 
PLASMA SULFACHLORPYRIDAZINE CONCENTRATION IN INDIVIDUAL* 
CATFISH AFTER INTRACARDIAC ADMINISTRA'riON 
Plasma Sulfachlorpyridazine Concentration (pg/ml) 
.Flic F2Ic F3Ic F4Ic F5Ic F6Ic F7Ic F8Ic F9Ic Mean SE 
1487.6 1742.8 1737.3 1032.0 1304.5 1669.1 1796.3 2364.0 1848.0 1664.6 ±124.3 
495.0 735.0 917.0 548.9 587.1 989.3 989.3 1154.0 947.1 818.1 ±77.3 
258.0 212.0 568.0 241.0 ----- 200.3 367.3 841.2 475.3 395.4 ±79.1 
----- 43.2 221.0 ----- 261.5 85.0 310.1 452.6 279.8 236.2 ±52.4 
----- ---- 162.1 124.1 134.4 76.8 140.6 260.7 91.5 141.4 ± 22 0 7 
150.6 46.0 71.1 113.5 70.2 68.5 89.3 147.8 84.5 93.5 ±12.1 
----- 43.7 59.4 101.5 66.9 67.7 69.5 114.9 65.1 73.6 ± 8 0 2 
87.5 ---- ---- ----- ---- ---- ---- -----
---- 41.1 50.9 112.9 44.9 56.7 56.7 73.0 39.1 59.4 ± 8 0 5 
32.9 ---- ---- -----
---- 26.3 28.6 40.4 32.2 44.2 46.0 37.2 17.2 34.0 ± 3 0 5 
8.6 16.8 22.1 18.9 16.5 17.9 38.2 24.5 7.6 19.0 ± 3 0 0 
--- 7.5 10.5 7.9 6.8 8.3 19.2 11.6 3.6 9.4 ±1.6 
--- 7.0 ---- 1.9 6.5 2.0 6.1 4.3 2.6 4.7 ±1.0 
*Individual catfish in this experiment were used for oral administration as well 
except for F3Ic, F5Ic and F7Ic which died a week after the intracardiac experiment. 
Ln 
-...J 
Time Post 
Injection 
{min) 
30 
60 
90 
120 
150 
180 
240 
300 
420 
600 
840 
1200 
TABLE IX 
PLASMA SULFACHLORPYRIDAZINE CONCENTRATION IN INDIVIDUAL* 
CATFISH AFTER ORAL ADMINISTRATION 
Plasma Sulfachlorpyridazine Concentration {pg/ml) 
FlOr F20r F30r F40r F50r F60r F70r F80r F90r 
3.6 2.0 1.5 3.4 1.5 3.0 0.7 8.4 1.8 
2.3 2.9 1.6 4.6 2.3 2.8 2.1 13.7 1.7 
3.8 --- 1.8 5.2 1.7 3.3 7.1 12.7 2.8 
3.1 10.7 2.7 6.8 2.4 5.8 7.6 16.5 5.2 
5.3 --- 3.6 5.2 1.6 4.7 9.6 17.8 4.7 
4.3 6.7 5.4 6.1 2.2 5.6 9.8 15.6 3.3 
3.8 4.7 9.6 10.3 1.8 7.1 10.4 18.4 11.3 
3.7 3.8 13.7 17.2 4.3 12.8 14.3 19.1 15.6 
4.0 2.4 8.8 11.1 4.8 6.6 11.9 18.6 27.1 
1.9 l.l 3.7 5.5 6.8 3.1 5.5 12.8 12.4 
0.2 1.4 2.3 2.3 5.5 1.6 1.7 5.2 4.6 
--- 0.5 1.7 1.9 1.9 1.3 1.2 0.5 3.2 
~~------------·----·-·--~·· 
Mean SE 
2.9 ± 0. 8 
3.8 ±1.3 
4.8 ±1.3 
6.8 ±1.5 
6.6 ±1.8 
6.6 ±1.3 
8.6 ±1.7 
11.6 ± 2. 0 
10.6 ± 2. 6 
5.9 ±1.4 
2.8 ± o. 6 
1.4 ± o. 3 
*Individuals in oral administrations were the same catfish used in intrcardiac 
administration except for F3 Or, F5 Or and F7 Oral. 
U1 
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TABLE X 
PHARMACOKINETIC PARAMETERS OF SULFACHLORPYRIDAZINE AFTER 
INTRACARDIAC ADMINISTRATION IN CHANNEL CATFISH 
Catfish II A B co p a. ~ k 12 k 21 
I. D. (pg/m1) (pg/m1) (pg/m1) (min-1) (min-1) (min-1) (min-1) 
F1Ic 2769.3 218.9 2988.2 0.38077 0.00537 0.29106 0.03267 
F2Ic 4020.4 54.8 4075.2 0.38933 0.00193 0.27907 0.00713 
F3Ic 1979.4 83.3 2062.7 0.16579 0.00236 0.11556 0.00896 
F4Ic 1336.7 182.9 1519.6 0.25200 0.00377 0.19392 0.03364 
F5Ic 1413.2 78.8 1491.9 0.14903 0.00239 0.10613 0.01012 
F6Ic 3548.7 111.5 3660.2 0.37059 0.00315 0.27801 0.01434 
F7Ic 1993.1 97.1 ?.090.2 0.17678 0.00193 0.13479 0.01004 
F8Ic 2518.3 158.5 2676.8 0.16619 0.00309 0.11620 0.01275 
F9Ic 2827.9 81.0 2908.9 0.22000 0.00330 0.13619 0.00933 
Mean II 2489.6 118.5 2608.2 0.25227 0.00303 0.18344 0.01547 
SE 11±304.0 ± 18.5 ± 300.5 ±0.03366 ±0.00036 ±0.02622 ± 0. 00343 
k e1 
(min-1) 
0.06221 
0.10505 
0.04363 
0.02821 
0.03517 
0.08139 
0.03387 
0.04033 
0.07778 
0.05640 
± 0.00886 
0\ 
0 
Catfisl: II t~a t ~B AUC 
I. D. (min) (min) (pg.min/m1) 
F1Ic 1.8 129 50906.3 
F2Ic 1.8 360 40658.7 
F3Ic 4.2 294 48807.0 
F4Ic 2.8 184 56982.9 
F5Ic 4.7 290 44786.0 
F6Ic 1.9 220 47201.5 
F7Ic 3.9 360 63948.4 
F8Ic 4.7 224 70712.1 
F9Ic 3.2 210 39269.2 
Mean II 3.2 252 51474.6 
SE II± o .4 ±26 ±3520.6 
TABLE X 
(Continiued) 
Vc vd(area) 
(m1/kg) (m1/kg) 
20.1 219.5 
14.7 766.7 
29.1 521.6 
39.5 279.6 
40.2 560.8 
16.4 403.6 
28.7 487.4 
22.4 274.3 
20.6 463.0 
25.7 441.8 
± 3.1 ±57.0 
vd(S) C1 B(area) 
(m1/kg) (m1/min/kg) 
232.5 1.18 
803.4 1.47 
538.'2 1. 23 
295.7 1.05 
591.9 1.34 
423.5 l. 27 
504.9 0.94 
292.2 0.85 
486.0 1.52 
463.1 l. 21 
±59.2 ±o.o8 
C1 
B(S) 
(m1/min/kg) 
1.24 
l. 56 
1.27 
1.11 
1.41 
l. 33 
0.97 
0.90 
1.60 
1..26 
±0.08 
0'1 
...... 
Catfish II 
TABLE XI 
PHARMACOKINETIC PARAMETERS OF SULFACHLORPYRIDAZINE AFTER 
ORAL ADMINISTRATION IN CHANNEL CATFISH 
B t~s s AUC(area) vd(area) CJB(area) 
I. D. II (pg/ml) (min) (min-1 ) (pg .min/ml} (ml/kg} (ml/min/kg} 
FlOr 4.6 282 0.00246 2401.9 479.8 1.18 
F20r 9.2 270 0.00257 3154.3 575.1 1.47 
F30r 21.2 291 0.00238 6194.9 488.5 1.16 
F40r 29.9 271 0.00256 7791.6 411.7 1.05 
F50r 28.5 305 0.00227 5855.3 514.3 1.17 
F60r 19.0 273 0.00254 5403.4 500.7 l. 27 
F70r 34.4 266 0.00261 7291.6 448.4 1.17 
F80r 102.4 170 0.00408 12848.6 208.2 0.85 
F90r 68.0 255 0.00272 12546.3 561.4 l. 52 
Mean 35.3 265 0.00269 7052.2 465.3 l. 20 
SE ± 10.4 ± 12 ± 0.00018 ±1213.8 ± 36.3 ± 0. 07 
Percent 
Bioavail. 
4.7 
7.8 
12.0* 
13.7 
11.4* 
11.4 
14.2* 
18.2 
31.9 
13.9 
± 2. 6 
*The bioavailability for these 3 fish is calculated from the mean AUC 
value for all f~sh givan intra~ardiac administrations. 
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TABLE XII 
THEORETICAL TISSUE CONCENTRATION* AND PERCENT DOSE 
ELIMINATED AFTER INTRACARDIAC ADMINISTRATION OF 
SULFACHLORPYRIDAZINE 
Time Post Tissue Concentration Percent Dose 
Injection (pg/ml) Eliminated 
(min) 
2 748.0 8.9 
5 1347.0 16.5 
8 1618.5 20.4 
14 1783.7 24.0 
20 1794.4 25.9 
60 1600.5 34.5 
120 1334.5 45.4 
240 927.7 62.0 
420 537.7 79.0 
600 311.7 87.2 
840 150.6 93.8 
1200 50.6 98.9 
*Mean of the plasma SCP concentrations over 
the same time period were used in the calculations. 
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'1'ABLE XIII 
THEORETICAL TISSUE CONCENTRATION* AND PERCENT DOSE** 
ELIMINATED AFTER ORAL ADMINISTRATION OF I 
SULFACHLORPYRIDAIZNE 
Time Post Tissue Concentration Percent bose 
Injection (pg/ml) Eliminated 
(min) 
30 8.0 18.8 
60 20.3 25.2 
90 32.2 29.4 
120 46.9 31.9 
150 58.9 35.8 
180 66.1 39.6 
240 84.4 44.1 
300 111.6 46.6 
420 122.5 57.9 
600 47.9 83.2 
840 1.2 98.8 
*Mean of the plasma SCP concentrations over 
the same time period were used in the calculations. 
**Percent of the absorbed (13%) dose. 
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APPENDIX C 
LIST OF PHARMACOKINETIC EQUATIONS GENERALLY 
APPLIED TO TWO COMPARTMENTAL OPEN MODEL 
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Dose to be administered= 
SCP Dose (60 mg) 
Body weight (kg) • 
kg 
0.693 
t~ ( Ct ) = Ct 
0.693 
t~ ( s ) = s 
A· S + B·a 
k21 = A+B 
a • B 
k = 
e1 k 21 
k 
12 
Dose 
Vc = 
• Cp 
Dose 
Vd (area) = AUC • S 
ke1 • Vc 
=-----
Cl = S Vd B(area) • (area) 
= k • Vc 
e1 
Bioavialibility = 
T 
AUC or • Sor 
AUC Ic • Src 
• 
-k 21 
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Equation (l) 
ml 
SCP Cone. 200 mg 
Equation (2) 
Equation (3) 
Equation (4) 
Equation (5) 
Equation (6) 
Equation (7) 
Equation (8) 
Equation (9) 
Equation (10) 
Equation {11) 
' Equat 1ion ( 12) 
Equa t 1ion { 13) 
l 
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